52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
French company BIOCORP forms partnership with Novo Nordisk on 'smart pens' to help those with diabetes
Novo Nordisk To Pay $100 Mln In Settlement Agreement
Exscientia Files For U.S. IPO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Biotechnology & Drugs
Novo Alle 1
Independent Chairman of the Board
Lars Fruergaard Joergensen
President, Chief Executive Officer
Vice Chairman of the Board
Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President
Maziar Mike Doustdar
Executive Vice President, International Operations
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
The pandemic is pushing more people to seek treatment for obesity, Novo Nordisk's top boss said on Thursday, referring to strong sales of the newly launched drug, Wegovy, which helped the drugmaker raise its earnings forecast for the full year.
Danish drugmaker Novo Nordisk will acquire U.S. drug developer Prothena Corp's experimental heart therapy, PRX004, in a deal that could be worth up to $1.23 billion, the companies said on Monday.
Novo Nordisk's new obesity drug Wegovy, far more efficient at causing weight loss in patients than similar drugs on the market, could capture sales of its existing obesity treatment Saxenda in the United States, the firm said on Monday.
The U.S. Food and Drug Administration (FDA) on Friday approved Danish drugmaker Novo Nordisk's once-weekly semaglutide drug as a treatment for obesity, a condition that affects nearly 70% of American adults.
Denmark's Novo Nordisk on Friday said the U.S. Food and Drug Administration (FDA) had approved its semaglutide drug as a treatment for obesity.
Denmark's Novo Nordisk raised its sales and profit forecasts on Wednesday after beating first-quarter earnings expectations, lifting shares in the world's biggest maker of diabetes drugs.
The foundation that controls Danish drug maker Novo Nordisk said on Monday it is in preliminary talks with the government about establishing local vaccine production.
Diabetes drugmaker Novo Nordisk forecast a rise in underlying sales and profit for 2021 on Wednesday and said it expected more Americans to get access to its drugs under the new Biden administration.
Diabetes drugmaker Novo Nordisk will start a late-stage clinical trial to test its semaglutide drug as a treatment for early Alzheimer's disease, it said on Wednesday.
Diabetes drug maker Novo Nordisk said on Friday it had agreed a $1.8 billion deal to acquire Emisphere Technologies, giving it control of a pill technology that it hopes will broaden sales to diabetics with an aversion to shots.
Danish diabetes drug maker Novo Nordisk will acquire U.S. Emisphere Technologies, which specialises in developing orally administered versions of drugs, in a deal totalling $1.8 billion, it said on Friday.
Drugmaker Novo Nordisk <NOVOb.CO> has seen a gradual recovery in the number of diabetics starting treatment, it said on Friday after reporting 2% sales growth in the third quarter.
European stock markets gained on Friday on rosy earnings forecasts from retailers Pandora and Zalando as well as drugmaker Novo Nordisk, with investors keeping an eye out for signs of fresh U.S. stimulus.
Diabetes drug maker Novo Nordisk <NOVOb.CO> raised its full-year earnings outlook slightly on Thursday as it managed to offset stagnant sales with cost cuts during the coronavirus crisis.
* REG-RYBELSUS® APPROVED IN JAPAN FOR THE TREATMENT OF TYPE 2 DIABETES
* REG-NOVO NORDISK SUCCESSFULLY COMPLETES AM833 PHASE 2 TRIAL AND PHASE 1 COMBINATION TRIAL WITH AM833 AND SEMAGLUTIDE IN OBESITY
* REG-SEMAGLUTIDE 2.4 MG SHOWS SUPERIOR WEIGHT LOSS VERSUS PLACEBO IN THE PHASE 3 TRIALS STEP 2 AND STEP 3, THEREBY SUCCESSFULLY COMPLETING THE PROGRAMME
* NOVO NORDISK ACQUIRES HBM PORTFOLIO COMPANY CORVIDIA THERAPEUTICS FOR UP TO USD 2.1 BILLION IN CASH Source text for Eikon: Further company coverage: (Gdansk Newsroom)
Novo Nordisk <NOVOb.CO> has agreed to buy AstraZeneca spin-off Corvidia Therapeutics for an initial $725 million as the world's largest diabetes drugmaker seeks to expand into cardiovascular disease treatments.
Novo Nordisk has agreed to buy AstraZeneca spin-off Corvidia Therapeutics for an initial $725 million as the world's largest diabetes drugmaker seeks to expand in cardiovascular disease.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.